• Home
  • Search Results
  • Interleukin-33 induces urokinase in human endothelial cells--possible impact on angiogenesis.

Interleukin-33 induces urokinase in human endothelial cells--possible impact on angiogenesis.

Journal of thrombosis and haemostasis : JTH (2014-04-08)
S Stojkovic, C Kaun, M Heinz, K A Krychtiuk, S Rauscher, C E Lemberger, R de Martin, M Gröger, P Petzelbauer, I Huk, K Huber, J Wojta, S Demyanets
ABSTRACT

Urokinase-type plasminogen activator (u-PA) plays a pivotal role in extracellular proteolysis and is thought to be critically involved in the modulation of angiogenesis. Interleukin (IL)-33 is a member of the IL-1 cytokine family, which is thought to act as danger signal that is released from cells after injury. IL-33 is involved in the pathogenesis of various inflammatory diseases and previously was shown to induce angiogenesis and inflammatory activation of endothelial cells. We investigated the impact of IL-33 on u-PA in endothelial cells as a new possible function for IL-33. We could demonstrate that IL-33 upregulated u-PA mRNA expression and protein production in human coronary artery and human umbilical vein endothelial cells in a time- and concentration-dependent manner via interaction with its receptor ST2 and activation of the nuclear factor-κB pathway but independent of autocrine IL-1-induced effects. The hydroxymethylglutaryl-coenzyme A reductase inhibitor simvastatin abrogated the IL-33-induced increase in u-PA, thus providing further evidence for pleiotropic effects of statins. IL-33 induced u-PA-dependent capillary-like tube formation and vessel sprouting. In human carotid atherosclerotic plaques (n = 16), u-PA mRNA positively correlated with IL-33 mRNA expression (r = 0.780, P < 0.001). Furthermore, IL-33 and u-PA protein were detected in endothelial cells in these samples using fluorescence immunohistochemistry. We hypothesize that IL-33, representing a danger signal that is released after tissue damage, in addition to its role in the inflammatory activation of endothelial cells, is involved in u-PA-driven angiogenesis, a process that has been shown before to be linked to inflammation in various pathologies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Simvastatin, ≥97% (HPLC), solid
Supelco
Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
DL-3-Hydroxy-3-methylglutaryl coenzyme A sodium salt hydrate, ≥90% (HPLC)
Supelco
Simvastatin, analytical standard
USP
Simvastatin, United States Pharmacopeia (USP) Reference Standard
Simvastatin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Anti-IL-33 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-IL-33 antibody produced in mouse, clone 12B3C4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-IL-33 antibody produced in mouse, clone 12H6D12, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
MISSION® esiRNA, targeting human SULT2A1
Sigma-Aldrich
Anti-IL33 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-IL33 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
MISSION® esiRNA, targeting human IL1RL1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Il1rl1

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.